Literature DB >> 23881543

Combination of angiographic and clinical characteristics for the prediction of clinical outcomes in elderly patients undergoing multivessel PCI.

Jan-Malte Sinning1, Tobias Asdonk, Christoph Erlhöfer, Mariuca Vasa-Nicotera, Eberhard Grube, Georg Nickenig, Nikos Werner.   

Abstract

BACKGROUND: Risk stratification is essential for the clinical decision-making process in elderly patients undergoing multivessel revascularization, since the optimal revascularization strategy remains subject of ongoing debate. AIMS: To assess the prognostic value of angiographic versus clinical characteristics for the prediction of a first adverse cardiac and cerebrovascular events (MACCE) (all-cause mortality, non-fatal myocardial infarction, stroke, and target lesion revascularization) and to develop a combined risk model.
METHODS: After multivessel percutaneous coronary intervention (MV-PCI), SYNTAX score and EuroSCORE were calculated as combined risk model in 328 elderly patients who were followed up for a first MACCE.
RESULTS: 328 patients with a mean age of 77.5 ± 5.1 years were followed up for 2.7 ± 1.5 years. A first MACCE occurred in 50.0 % (164/328) of the patients. To improve predictability, a combined risk score model with receiver operating characteristic curve validated cut-off values for EuroSCORE (>5 %) and SYNTAX score (>25) was developed. High risk patients had a 3.5-fold higher risk for MACCE after 3 years (HR 7.1, 95 % CI 1.9-6.5; p < 0.001).
CONCLUSIONS: For adequate risk assessment in elderly patients undergoing MV-PCI, consideration of both comorbidities and coronary anatomic complexity is essential. A combined angiographic and clinical risk score provides superior prediction of 3-year MACCE risk in elderly patients.

Entities:  

Mesh:

Year:  2013        PMID: 23881543     DOI: 10.1007/s00392-013-0599-5

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  33 in total

1.  Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients.

Authors:  F Roques; S A Nashef; P Michel; E Gauducheau; C de Vincentiis; E Baudet; J Cortina; M David; A Faichney; F Gabrielle; E Gams; A Harjula; M T Jones; P P Pintor; R Salamon; L Thulin
Journal:  Eur J Cardiothorac Surg       Date:  1999-06       Impact factor: 4.191

2.  Logistic or additive EuroSCORE for high-risk patients?

Authors:  Philippe Michel; Francois Roques; Samer A M Nashef
Journal:  Eur J Cardiothorac Surg       Date:  2003-05       Impact factor: 4.191

3.  A new tool for the risk stratification of patients with complex coronary artery disease: the Clinical SYNTAX Score.

Authors:  Scot Garg; Giovanna Sarno; Hector M Garcia-Garcia; Chrysafios Girasis; Joanna Wykrzykowska; Keith D Dawkins; Patrick W Serruys
Journal:  Circ Cardiovasc Interv       Date:  2010-07-20       Impact factor: 6.546

4.  Usefulness of the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left main coronary artery disease.

Authors:  Davide Capodanno; Maria Elena Di Salvo; Glauco Cincotta; Marco Miano; Claudia Tamburino; Corrado Tamburino
Journal:  Circ Cardiovasc Interv       Date:  2009-06-30       Impact factor: 6.546

5.  Favorable long-term survival in patients undergoing multivessel-PCI compared to predicted prognosis of CABG estimated by EuroSCORE: procedural and clinical determinants of long-term outcome.

Authors:  Ralf Lehmann; Stephan Fichtlscherer; Volker Schächinger; Laura Held; Carola Hobler; Gregor Baier; Andreas M Zeiher; Ioakim Spyridopoulos
Journal:  J Interv Cardiol       Date:  2009-09-02       Impact factor: 2.279

6.  Safety and effectiveness of percutaneous coronary intervention (PCI) in elderly patients. a 5-year consecutive study of 201 cases with PCI.

Authors:  Qingwei Chen; Yan Yang; Ying Liu; Dazhi Ke; Qing Wu; Guiqiong Li
Journal:  Arch Gerontol Geriatr       Date:  2010-02-11       Impact factor: 3.250

Review 7.  Clinical and angiographic risk assessment in patients with left main stem lesions.

Authors:  Scot Garg; Gregg W Stone; Arie-Peter Kappetein; Joseph F Sabik; Charles Simonton; Patrick W Serruys
Journal:  JACC Cardiovasc Interv       Date:  2010-09       Impact factor: 11.195

Review 8.  Comparison of coronary revascularization procedures in octogenarians: a systematic review and meta-analysis.

Authors:  Stephen H McKellar; Morgan L Brown; Robert L Frye; Hartzell V Schaff; Thoralf M Sundt
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-09-30

9.  Usefulness of the logistic clinical SYNTAX score for predicting 1-year mortality in patients undergoing percutaneous coronary intervention of the left main coronary artery.

Authors:  Davide Capodanno; Daniele Giacoppo; Fabio Dipasqua; Eligio Miccichè; Carmelo Licitra; Maria Elena Di Salvo; Bruno Francaviglia; Carmelo Grasso; Alessio La Manna; Carmelo Sgroi; Corrado Tamburino
Journal:  Catheter Cardiovasc Interv       Date:  2013-06-03       Impact factor: 2.692

10.  Assessment of the SYNTAX score in the Syntax study.

Authors:  Patrick W Serruys; Yoshinobu Onuma; Scot Garg; Giovanna Sarno; Marcel van den Brand; Arie-Pieter Kappetein; Nic Van Dyck; Michael Mack; David Holmes; Ted Feldman; Marie-Claude Morice; Antonio Colombo; Eric Bass; Katrin Leadley; Keith D Dawkins; Gerrit-Anne van Es; Marie-Angèle M Morel; Friedrich W Mohr
Journal:  EuroIntervention       Date:  2009-05       Impact factor: 6.534

View more
  7 in total

1.  SYNTAX score-0 patients: risk stratification in nonobstructive coronary artery disease.

Authors:  Christoph Sinning; Elvin Zengin; Christoph Waldeyer; Moritz Seiffert; Renate B Schnabel; Edith Lubos; Tanja Zeller; Christoph Bickel; Stefan Blankenberg; Peter M Clemmensen; Dirk Westermann
Journal:  Clin Res Cardiol       Date:  2016-06-30       Impact factor: 5.460

2.  Long-term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: results from the MONICA/KORA Myocardial Infarction Registry.

Authors:  Ute Amann; Inge Kirchberger; Margit Heier; Hildegard Golüke; Wolfgang von Scheidt; Bernhard Kuch; Annette Peters; Christa Meisinger
Journal:  Clin Res Cardiol       Date:  2014-03-07       Impact factor: 5.460

3.  Indication and short-term clinical outcomes of high-risk percutaneous coronary intervention with microaxial Impella® pump: results from the German Impella® registry.

Authors:  Stefan Baumann; Nikos Werner; Karim Ibrahim; Ralf Westenfeld; Fadi Al-Rashid; Jan-Malte Sinning; Dirk Westermann; Andreas Schäfer; Konstantinos Karatolios; Timm Bauer; Tobias Becher; Ibrahim Akin
Journal:  Clin Res Cardiol       Date:  2018-03-08       Impact factor: 5.460

4.  Predictive value of SYNTAX score II for clinical outcomes in octogenarian undergoing percutaneous coronary intervention.

Authors:  Evan Kurniawan; Feng-Hua Ding; Qi Zhang; Zhen-Kun Yang; Jian Hu; Wei-Feng Shen; Rui-Yan Zhang
Journal:  J Geriatr Cardiol       Date:  2016-09       Impact factor: 3.327

Review 5.  Application of the SYNTAX score in interventional cardiology: A systematic review and meta-analysis.

Authors:  Pravesh Kumar Bundhun; Yashna Sookharee; Anita Bholee; Feng Huang
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

6.  A fitting machine learning prediction model for short-term mortality following percutaneous catheterization intervention: a nationwide population-based study.

Authors:  Meng-Hsuen Hsieh; Shih-Yi Lin; Cheng-Li Lin; Meng-Ju Hsieh; Wu-Huei Hsu; Shu-Woei Ju; Cheng-Chieh Lin; Chung Y Hsu; Chia-Hung Kao
Journal:  Ann Transl Med       Date:  2019-12

7.  Age-dependent impact of the SYNTAX-score on longer-term mortality after percutaneous coronary intervention in an all-comer population.

Authors:  Madeleine Eickhoff; Stefanie Schüpke; Alexander Khandoga; Julia Fabian; Moritz Baquet; David Jochheim; David Grundmann; Manuela Thienel; Axel Bauer; Hans Theiss; Stefan Brunner; Jörg Hausleiter; Steffen Massberg; Julinda Mehilli
Journal:  J Geriatr Cardiol       Date:  2018-09-28       Impact factor: 3.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.